Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited will convene a board meeting on Monday, 12 October 2026, to consider and approve the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs) in one or more tranches, on a private placement basis, for an aggregate amount not exceeding Rs 15,000 crore.

Sun Pharmaceutical Industries Limited will close its trading window for share transactions starting October 1, 2026, and continuing until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, according to a filing with the National Stock Exchange of India Limited and BSE Limited.

Sun Pharmaceutical Industries Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1873.4, down 0.66% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75160.39, down 0.55%.Sun Pharmaceutical Industries Ltd has eased around 3.65% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 6.8 lakh shares today, compared to the daily average of 15.37 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1881.5, down 0.83% on the day. Sun Pharmaceutical Industries Ltd jumped 17.57% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.The PE of the stock is 141.76 based on TTM earnings ending June 26.

Sun Pharmaceutical Industries Ltd announced credit rating actions from both Moody’s and S&P Global, reflecting the company’s business and financial strength. Moody’s assigned a Baa1 (stable outlook) to its Long-Term Issuer Credit Rating and Issuer Rating, and a Ba3 rating, currently under review for upgrade, to the $11.75 billion Organon Moody’s also noted that Sun Pharma’s debt ratings are two notches above the Indian sovereign, with a Moody’s-adjusted gross debt/EBITDA leverage expected to be around 3.0x (pro-forma March 2027), decreasing to about 2.0x within 18 months, and assigned a Gross Debt rating of Baa1, two notches below a scorecard-indicated outcome of A2. S&P Global assigned a BBB+ (stable outlook) to its Long-Term Issuer Credit Rating and Preliminary Rating, along with ratings of BBB+ (stable outlook) to Long-term investments totaling INR10.5 billion, and preliminary ratings of BBB+/Stable for Foreign currency and Local currency issuer credit ratings, alongside a stand-alone credit profile and group credit profile of bbb+. The company maintains $3.6 billion in cash as of March 31, 2026, and has secured $12 billion in committed financing and a $12 billion Acquisition Financing Bridge Loan, while also possessing corporate bonds, debentures, notes, commercial paper, and preferred stock, for which issuers typically pay for ratings.

Sun Pharmaceutical Industries Ltd announced that CRISIL Ratings Limited ("CRISIL") has removed the ‘Rating Watch with Developing Implications’ status and reaffirmed the rating assigned to the Company's long-term bank facilities at ‘CRISIL AAA/Stable’ (Reaffirmed; Removed from ‘Rating Watch with Developing Implications’), referencing a prior communication dated May 7, 2026, which initially detailed CRISIL’s reaffirmation of the ‘CRISIL AAA’ rating with the aforementioned watch status following an announcement on April 27, 2026; no other rating agencies or instruments are mentioned in the communication.

Sun Pharmaceutical Industries Ltd share price ticked higher by 0.55% to Rs 2000.75 after the company's net profit grew slightly 6.87% to Rs 2910.8 crore, while revenue from operations improved marginally 4.28% to Rs 15183.55 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 5.84%. It has marginally improved by 2.27% over last one week and jumped by 15.01% in last one month while the market capitalization of Sun Pharmaceutical Industries Ltd has inched up 3.08% and 10.65% in the same period respectively. Profit before tax (PBT) of Sun Pharmaceutical Industries Ltd stood at Rs 4098.81 crore in Q2 FY26, expanding by 29.19% year-on-year, and jumping 15.42% quarter-on-quarter. EBITDA came in at Rs 3694 crore, declining 3.73% YoY and rising 5.67% sequentially. Total expenses saw a slight increase of 1.64% to Rs 11620.93 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 2026.28 crore, slightly declining by 7.16% YoY, while employee benefits expense was at Rs 3227.23 crore, improving by 9.01% YoY. For the TTM ended FY26, revenue from operations rose 11.87% to Rs 58220.11 crore, while net profit saw a mild growth of 5.32% to Rs 11564.52 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1366811% to Rs 15759.68 crore, and PBT saw a minor gain of 9.94% to Rs 15118.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 12419.18 crore in FY26, as against Rs 14072.09 crore in FY25. Sun Pharmaceutical Industries Ltd jumped 15.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.

Net profit of Sun Pharmaceutical Industries rose 27.04% to Rs 2894.79 crore in the quarter ended June 2026 as against Rs 2278.63 crore during the previous quarter ended June 2025. Sales rose 10.14% to Rs 15183.55 crore in the quarter ended June 2026 as against Rs 13786.07 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales15183.5513786.07 10 OPM %29.1031.20 - PBDT5041.624691.32 7 PBT4302.903990.77 8 NP2894.792278.63 27 Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 2033.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24401.75. The Sensex is at 78214.53, up 0.37%. Sun Pharmaceutical Industries Ltd has gained around 8.94% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has gained around 5.81% in last one month and is currently quoting at 26346.05, up 1.14% on the day. The volume in the stock stood at 10.53 lakh shares today, compared to the daily average of 23.07 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 2037, up 1.49% on the day. Sun Pharmaceutical Industries Ltd is up 24.75% in last one year as compared to a 0.67% slide in NIFTY and a 21.06% slide in the Nifty Pharma index.The PE of the stock is 163.06 based on TTM earnings ending March 26.

Sun Pharmaceutical Industries Limited announced it received approval from Brazil’s ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of type 2 diabetes, planning a launch in the coming days in partnership with Hypera Pharma. The semaglutide injectable market in Brazil is approximately USD 413 million, according to IQVIA data from June 2026.

Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.